Tzield for Newly Diagnosed Type 1 Diabetes
Quick Facts
What Is Tzield and How Does It Work in Type 1 Diabetes?
Tzield, the brand name for teplizumab-mzwv, targets CD3 on T cells, a key part of the immune system involved in the autoimmune destruction of pancreatic beta cells. Type 1 diabetes develops when the body progressively loses the ability to make insulin, and preserving even partial natural insulin production can matter for glucose stability and long-term management.
The drug was first approved by the FDA in 2022 to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older with stage 2 disease. The newly reported approval for children and teens with newly diagnosed stage 3 disease is clinically important because many patients still have measurable beta-cell function at diagnosis, creating a narrow treatment window for immune intervention.
Why Is Preserving Natural Insulin Production Important After Diagnosis?
After type 1 diabetes is diagnosed, many children enter a period sometimes called the partial remission or honeymoon phase, when the pancreas can still produce some insulin. Clinicians value this remaining function because it may support smoother glucose control, lower insulin requirements, and fewer large glucose swings, although insulin therapy remains essential.
Immunotherapy does not replace insulin, glucose monitoring, nutrition planning, or emergency education for hypoglycemia and diabetic ketoacidosis. Instead, it adds a disease-modifying strategy aimed at the immune process behind beta-cell loss, which is different from standard glucose-lowering treatment.
What Should Families Ask Before Starting Tzield?
Tzield is not a simple daily pill; it is given as an intravenous treatment course and requires medical supervision. Families should discuss whether the child meets the approved indication, how beta-cell function will be assessed, and what monitoring is needed before, during, and after treatment.
Known safety considerations for teplizumab include immune-related effects, rash, headache, and changes in certain blood counts or liver tests, as described in FDA materials for the original approval. Decisions should be individualized with a pediatric endocrinology team because the potential benefit is preservation of function, not a cure for type 1 diabetes.
Frequently Asked Questions
No. Tzield does not cure type 1 diabetes or eliminate the need for insulin. It is intended to modify the autoimmune process and help preserve insulin-producing beta-cell function.
According to the reported FDA approval, the expanded use applies to children and adolescents ages 8 to 17 with newly diagnosed stage 3 type 1 diabetes. Eligibility should be confirmed by a diabetes specialist.
No. Insulin replaces a hormone the body cannot make enough of, while Tzield is an immune therapy that targets T cells involved in beta-cell destruction.
References
- WebMD. FDA Approves Tzield to Slow the Decline of Natural Insulin Production in People 8-17 Years Old With Newly Diagnosed Stage 3 Type 1 Diabetes. June 2026.
- U.S. Food and Drug Administration. FDA approves first drug that can delay onset of type 1 diabetes. 2022.
- Herold KC et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. New England Journal of Medicine. 2019.